Showing 2 posts of 2 posts found.


BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …


FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

March 26, 2020
Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …

Latest content